These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24405703)

  • 21. Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases.
    Sun S; Zhang Z; Kodumuru V; Pokrovskaia N; Fonarev J; Jia Q; Leung PY; Tran J; Ratkay LG; McLaren DG; Radomski C; Chowdhury S; Fu J; Hubbard B; Winther MD; Dales NA
    Bioorg Med Chem Lett; 2014 Jan; 24(2):520-5. PubMed ID: 24374272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in stearoyl-CoA desaturase 1 inhibitors for dyslipidemia and obesity.
    Liu G
    Curr Top Med Chem; 2010; 10(4):419-33. PubMed ID: 20180759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel SCD1 inhibitors: 5-alkyl-4,5-dihydro-3H-spiro[1,5-benzoxazepine-2,4'-piperidine] analogs.
    Uto Y; Ueno Y; Kiyotsuka Y; Miyazawa Y; Kurata H; Ogata T; Takagi T; Wakimoto S; Ohsumi J
    Eur J Med Chem; 2011 May; 46(5):1892-6. PubMed ID: 21356569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of liver-targeted inhibitors of stearoyl-CoA desaturase (SCD1).
    Deng Y; Yang Z; Shipps GW; Lo SM; West R; Hwa J; Zheng S; Farley C; Lachowicz J; van Heek M; Bass AS; Sinha DP; Mahon CR; Cartwright ME
    Bioorg Med Chem Lett; 2013 Feb; 23(3):791-6. PubMed ID: 23265904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thiazole analog as stearoyl-CoA desaturase 1 inhibitor.
    Li CS; Belair L; Guay J; Murgasva R; Sturkenboom W; Ramtohul YK; Zhang L; Huang Z
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5214-7. PubMed ID: 19632834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models.
    Issandou M; Bouillot A; Brusq JM; Forest MC; Grillot D; Guillard R; Martin S; Michiels C; Sulpice T; Daugan A
    Eur J Pharmacol; 2009 Sep; 618(1-3):28-36. PubMed ID: 19616540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological inhibition of stearoyl CoA desaturase in the skin induces atrophy of the sebaceous glands.
    Meingassner JG; Aschauer H; Winiski AP; Dales N; Yowe D; Winther MD; Zhang Z; Stütz A; Billich A
    J Invest Dermatol; 2013 Aug; 133(8):2091-4. PubMed ID: 23446987
    [No Abstract]   [Full Text] [Related]  

  • 28. Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors.
    Koltun DO; Parkhill EQ; Vasilevich NI; Glushkov AI; Zilbershtein TM; Ivanov AV; Cole AG; Henderson I; Zautke NA; Brunn SA; Mollova N; Leung K; Chisholm JW; Zablocki J
    Bioorg Med Chem Lett; 2009 Apr; 19(7):2048-52. PubMed ID: 19249203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stearoyl-CoA desaturase inhibitors: update on patented compounds.
    Liu G
    Expert Opin Ther Pat; 2009 Sep; 19(9):1169-91. PubMed ID: 19691439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase.
    Dobrzyn P; Dobrzyn A
    Expert Opin Ther Pat; 2010 Jun; 20(6):849-53. PubMed ID: 20205608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine].
    Uto Y; Kiyotsuka Y; Ueno Y; Miyazawa Y; Kurata H; Ogata T; Deguchi T; Yamada M; Watanabe N; Konishi M; Kurikawa N; Takagi T; Wakimoto S; Kono K; Ohsumi J
    Bioorg Med Chem Lett; 2010 Jan; 20(2):746-54. PubMed ID: 20006498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.
    Ramtohul YK; Black C; Chan CC; Crane S; Guay J; Guiral S; Huang Z; Oballa R; Xu LJ; Zhang L; Li CS
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1593-7. PubMed ID: 20137926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of stearoyl-CoA desaturase-1 function induces a palmitoyl-CoA Delta6 desaturase and represses the stearoyl-CoA desaturase-3 gene in the preputial glands of the mouse.
    Miyazaki M; Gomez FE; Ntambi JM
    J Lipid Res; 2002 Dec; 43(12):2146-54. PubMed ID: 12454277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a novel LC/MS method to quantitate cellular stearoyl-CoA desaturase activity.
    Dillon R; Greig MJ; Bhat BG
    Anal Chim Acta; 2008 Oct; 627(1):99-104. PubMed ID: 18790132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thia fatty acids as substrates and inhibitors of stearoyl-CoA desaturase.
    Høvik KE; Spydevold OS; Bremer J
    Biochim Biophys Acta; 1997 Nov; 1349(3):251-6. PubMed ID: 9434139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of 1-(4-phenoxypiperidin-1-yl)-2-arylaminoethanone stearoyl-CoA desaturase 1 inhibitors.
    Zhao H; Serby MD; Smith HT; Cao N; Suhar TS; Surowy TK; Camp HS; Collins CA; Sham HL; Liu G
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3388-91. PubMed ID: 17434733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma-based approach to measure target engagement for liver-targeting stearoyl-CoA desaturase 1 inhibitors.
    Landry F; Chan CC; Huang Z; Leclair G; Li CS; Oballa R; Zhang L; Bateman K
    J Lipid Res; 2011 Aug; 52(8):1494-9. PubMed ID: 21642745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects.
    Sun S; Zhang Z; Raina V; Pokrovskaia N; Hou D; Namdari R; Khakh K; Ratkay LG; McLaren DG; Mork M; Fu J; Ferreira S; Hubbard B; Winther MD; Dales N
    Bioorg Med Chem Lett; 2014 Jan; 24(2):526-31. PubMed ID: 24370012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide.
    Uto Y; Ogata T; Harada J; Kiyotsuka Y; Ueno Y; Miyazawa Y; Kurata H; Deguchi T; Watanabe N; Takagi T; Wakimoto S; Okuyama R; Abe M; Kurikawa N; Kawamura S; Yamato M; Osumi J
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4151-8. PubMed ID: 19540759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and its biological evaluation.
    Uto Y; Ogata T; Kiyotsuka Y; Miyazawa Y; Ueno Y; Kurata H; Deguchi T; Yamada M; Watanabe N; Takagi T; Wakimoto S; Okuyama R; Konishi M; Kurikawa N; Kono K; Osumi J
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4159-66. PubMed ID: 19541482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.